Menu
← Oncology Approval Tracker
FDA DECISION ·
Degevma
denosumab-adet · Teva Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Xgeva biosimilar to prevent skeletal-related events in multiple myeloma or solid tumor bone metastases, treat certain unresectable or high-morbidity giant cell tumors of bone, and treat hypercalcemia of malignancy refractory to bisphosphonates.
LAMPGEN ANALYSIS
Why it matters
The decision adds a biosimilar across tumor-related bone uses. The Xgeva-referenced presentation and its indications differ from the Prolia-referenced formulation.
What research teams should watch
Match the product and indication in pharmacy records. Monitor product availability and keep calcium and dental safety workflows visible.
PRIMARY RECORDS